Ceapro Inc V.CZO

Possibilities and realities

[fossi_2002]

First of all, I would like to apologize to all those who did not catch the beginning of the discussion.
But that was because Stockhouse deleted a comment from ISALoser - and my reply along with it.
I presuppose once again that I have been working with approx. 4 mill. shares of Ceapro, I am certainly not one of those who are negative about the future of this stock.
But it is also part of it, between the doomsayers like ISA... and Hart... and the permanent optimist like Proph... to differentiate.
Why someone like ISA... is still a shareholder after thousands of negative comments, can only be understood by himself. One should be able to trust someone who thinks absolutely nothing of the Board of Management, the company and its products - to simply sell the shares. But maybe he is just afraid of missing out.

In 2014, Ceapro began the transformation process in the direction of pharmaceuticals. - and yes Proph... it takes time to achieve success in this sector.
Until today the result is 0:3
CoQ10 drink first too expensive and now according to Proph never strong as today.
Is it not so that the fish must taste the bait - and not the angler? So - why don't the fish bite - when our product is so great?
The cholesterol reducer - a business and financial failure!
Wound healing - another failure?!

Does anyone really believe that the announcement of a Phase I study will cause the share price to explode?
Perhaps one should first look at the current presentation, which assumes a time window of 3-5 years.

I have said before that I consider it a joke if a company that is expanding in the pharmaceutical sector can afford to do without a proper research department.

Hope - imagination - future-rich pipeline - all right - but at some point this must also be reflected in reliable figures.

The Ceapro share is cheap - I fully agree with that. Of course, sales fluctuate from quarter to quarter. In our case, we had a very strong 1st half - and a weak 2nd half. Why can't you just accept that? I'm curious if the figures for the 1st quarter of 2023 don't reach the figures for 2022 - are we then also only talking about quarterly differences?
In terms of Ceapro's share price performance, we have seen a fluctuation range between $0.40 and $0.80 for a long time.
L

To classify this performance as exceptional - just because the biotechnology sector has done even worse - does not exactly make me cheer, in any case. It all depends on what you are satisfied with.
Ronnie Miller is certainly a top address - hopefully he won't just take on the role of breakfast director for us.
In summary, I am optimistic for Ceapro in the medium term, especially with regard to the scale-up process of PGX.
However, since Gilles cannot decide to put the shareholder value principle first and his information policy is still a disaster, I will not give him my approval at the AGM.